EXTRAHEPATIC CHOLANGIOCARCINOMA

This study is testing whether giving chemotherapy (capecitabine or S-1) together with radiation after surgery can help prevent bile duct and gallbladder cancers from coming back. It includes 92 patients whose cancers had high-risk features, like positive lymph nodes or narrow sur…

This phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …

This global Phase 3 trial is testing whether adding the experimental immunotherapy rilvegostomig to standard chemotherapy helps people with advanced biliary tract cancer live longer, compared to adding the approved drug durvalumab. About 1,100 participants with inoperable or meta…

This study tests a new therapy called EB-HC01, which uses specially engineered natural killer (NK) immune cells to attack cancer cells that have two specific markers (HER2 and CEACAM5). The trial enrolls adults with advanced bile duct or gallbladder cancers that have worsened aft…

This study tests a new combination of four drugs—two standard chemotherapies plus an immunotherapy and a cholesterol drug—in people with advanced bile duct cancer. All 29 participants will receive the same treatment. Researchers will check how many patients see their tumors shrin…

This phase 2 trial is testing a new approach for people with advanced bile duct cancer that has caused a blockage. The treatment combines a light-activated drug (sodium porphyrin) with standard chemotherapy (gemcitabine and cisplatin). The goal is to see if this combination can h…

This study tests whether a procedure called endobiliary radiofrequency ablation (EB-RFA) can help people with advanced bile duct cancer live longer. EB-RFA uses a catheter to deliver heat directly to the tumor inside the bile duct. Half of the 120 participants will receive EB-RFA…

This phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy or the targeted drug lenvatinib can help people with advanced biliary tract cancer live longer and control their tumors better. The study will enroll 60 adults whose cancer …

This early-phase study tests whether adding heat therapy and a special type of radiation to standard chemoimmunotherapy is safe and feasible for people with advanced bile duct cancer that cannot be removed by surgery. About 15 participants will receive the combination treatment. …

This phase 2 trial is testing whether adding two immunotherapy drugs (tuvonralimab and iparomlimab) to standard chemotherapy before surgery can improve outcomes for people with bile duct or gallbladder cancer. About 45 adults with resectable or borderline-resectable cancer will r…

This phase 2 trial is testing whether combining radiofrequency ablation (a heat treatment) with chemotherapy and the immunotherapy drug durvalumab can improve survival in people with advanced bile duct cancer that cannot be removed by surgery. The study will enroll 42 participant…

This study tests a combination of four drugs—gemcitabine, cisplatin, nab-paclitaxel, and tislelizumab—in people with advanced biliary tract cancer (bile duct or gallbladder cancer) that has not been treated before. The goal is to see if this mix can shrink tumors and improve surv…

This study is testing a blood test that looks for DNA changes from tumors to help diagnose and manage biliary tract cancers, which are often found late and have a low survival rate. Researchers will enroll 1,800 participants with confirmed cancers to see how accurate the test is.…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find genetic changes in advanced bile duct cancer as well as a traditional tissue biopsy. The goal is to make it easier and less invasive to identify which patients might benefit from targeted therapi…